Literature DB >> 26656458

Hypertension in 2015: Resistant hypertension: impact and evolving treatment options.

Lilach O Lerman1, Stephen C Textor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26656458      PMCID： PMC4966555          DOI： 10.1038/nrneph.2015.199

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.

Authors:  Guillaume Bobrie; Michael Frank; Michel Azizi; Séverine Peyrard; Pierre Boutouyrie; Gilles Chatellier; Stéphane Laurent; Joël Menard; Pierre-François Plouin
Journal:  J Hypertens       Date:  2012-08       Impact factor: 4.844

2.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors:  Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal:  Lancet       Date:  2010-11-17       Impact factor: 79.321

3.  True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence.

Authors:  Hélène Beaussier; Pierre Boutouyrie; Guillaume Bobrie; Michael Frank; Stéphane Laurent; François Coudoré; Michel Azizi
Journal:  J Hypertens       Date:  2015-12       Impact factor: 4.844

4.  Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; In Lu A Liu; David A Calhoun; Elizabeth A McGlynn; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

5.  First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

Authors:  Michael Böhm; Felix Mahfoud; Christian Ukena; Uta C Hoppe; Krzysztof Narkiewicz; Manuela Negoita; Luis Ruilope; Markus P Schlaich; Roland E Schmieder; Robert Whitbourn; Bryan Williams; Uwe Zeymer; Andreas Zirlik; Giuseppe Mancia
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

Review 6.  New approaches in the treatment of hypertension.

Authors:  Suzanne Oparil; Roland E Schmieder
Journal:  Circ Res       Date:  2015-03-13       Impact factor: 17.367

7.  A controlled trial of renal denervation for resistant hypertension.

Authors:  Deepak L Bhatt; David E Kandzari; William W O'Neill; Ralph D'Agostino; John M Flack; Barry T Katzen; Martin B Leon; Minglei Liu; Laura Mauri; Manuela Negoita; Sidney A Cohen; Suzanne Oparil; Krishna Rocha-Singh; Raymond R Townsend; George L Bakris
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

8.  Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; Kristi Reynolds; David A Calhoun; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Kidney Int       Date:  2015-05-06       Impact factor: 10.612

9.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
  10 in total
  2 in total

1.  Optimizing identification of resistant hypertension: Computable phenotype development and validation.

Authors:  Caitrin W McDonough; Kyle Babcock; Kristen Chucri; Dana C Crawford; Jiang Bian; François Modave; Rhonda M Cooper-DeHoff; William R Hogan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2020-08-26       Impact factor: 2.890

2.  Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES).

Authors:  Katerina R Kaczmarski; Stephen M Sozio; Jingsha Chen; Yingying Sang; Tariq Shafi
Journal:  BMC Nephrol       Date:  2019-04-25       Impact factor: 2.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.